A/S Genmab在Merus股份中购买了122M美元,将其股份增加到72.8M,尽管股票交易低于购买价。 A/S Genmab bought $122M in Merus shares, boosting its stake to 72.8M, despite stock trading below purchase price.

Merus(MRUS)的主要股东A/S Genmab在2024年12月16日至26日期间购买了126万股,每股97.00美元,投资约1.22亿美元,股份增加至7 280万美元,价值70.6亿美元。 A/S Genmab, a major shareholder of Merus (MRUS), bought 1.26 million shares between December 16 and 26, 2024, at $97.00 per share, investing about $122 million and increasing its stake to 72.8 million shares, valued at $7.06 billion. 12月30日Merus股票交易额为90.00美元,低于12个月最高额97.14美元,而12个月最高额为97.14美元,在证交会档案中披露的这些采购反映了持续的信心。 The purchases, disclosed in SEC filings, reflect continued confidence despite Merus stock trading at $90.00 on December 30, down from a 12-month high of $97.14. 该公司的市场上限为68.3亿美元,分析家将它平均评为“持有”,目标价格为93.56美元。 The company’s market cap stood at $6.83 billion, with analysts rating it a "hold" on average and a target price of $93.56.